1-6 of 6
Erik van Werkhoven
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Lennart Kester, Danielle Seinstra, Annelot G.J. van Rossum, Claire Vennin, Marlous Hoogstraat, Daphne van der Velden, Mark Opdam, Erik van Werkhoven, Kerstin Hahn, Iris Nederlof, Ester H. Lips, Ingrid A.M. Mandjes, A. Elise van Leeuwen-Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra D. Bakker, Emiel J. Rutgers, Hugo M. Horlings, Jelle Wesseling, Emile E. Voest, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Alexander van Oudenaarden, Sabine C. Linn, Jacco van Rheenen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 960–971.
https://doi.org/10.1158/1078-0432.CCR-21-1442
Published: 01 March 2022
View article titled, Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Open the PDF for Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments in another window
Includes: Supplementary data
Journal Articles

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Hanneke van der Wijngaart, Louisa R. Hoes, J. Maxime van Berge Henegouwen, Daphne L. van der Velden, Laurien J. Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie G.J. Robbrecht, Mariette Labots, Derk Jan A. de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104
Published: 15 November 2021
View article titled, Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Open the PDF for Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1256–1266.
https://doi.org/10.1158/1078-0432.CCR-20-2551
Published: 01 March 2021
View article titled, Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Open the PDF for Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen, Meiling Gao, Mariette Schrier, Ingrid A.M. Mandjes, Javier Garcia-Corbacho, Anne-Laure Vallier, Greig Dougall, Erik van Werkhoven, Constanza Linossi, Sanjeev Kumar, Harm van Tinteren, Maurizio Callari, Emma Beddowes, José-Manuel Perez-Garcia, Hilde Rosing, Else Platte, Petra Nederlof, Margaret Schot, Aurelia de Vries Schultink, René Bernards, Cristina Saura, William Gallagher, Javier Cortès, Carlos Caldas, Sabine C. Linn
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6598–6605.
https://doi.org/10.1158/1078-0432.CCR-19-0508
Published: 15 November 2019
View article titled, POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Open the PDF for POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Tessa G. Steenbruggen, Maartje van Seijen, Liselore M. Janssen, Mette S. van Ramshorst, Erik van Werkhoven, Marie-Jeanne T.D.F. Vrancken Peeters, Jelle Wesseling, Esther H. Lips, Gabe S. Sonke
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4985–4992.
https://doi.org/10.1158/1078-0432.CCR-19-0560
Published: 15 August 2019
View article titled, Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Open the PDF for Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore in another window
Includes: Supplementary data